Robert Bermel, MD

• National Multiple Sclerosis Society Research Grant: "Advanced imaging methods to study recovery from acute optic neuritis"
• Program Committee - American Society of Neuroimaging
• Regular volunteer speaker for the National Multiple Sclerosis Society

• 2003 American Society of Neuroimaging William Oldendorf Award for Outstanding Neuroimaging Research. Presented at the ASN Annual Meeting, New Orleans, LA March 7, 2003 for the work entitled: \"Gray matter T2 hypointensity predicts longitudinal brain atrophy in MS: effect of interferon beta-1a\".
• 2003 American Academy of Neurology Medical Student Prize for Excellence in Neurology. Presented at University at Buffalo School of Medicine commencement May 23, 2003.
• 2003 State University of New York at Buffalo Baccelli Award for Most Outstanding Research. Presented at University at Buffalo School of Medicine commencement May 23, 2003.
• 2001 American Academy of Neurology G. Milton Shy Award in Clinical Neurology. Presented at the AAN Annual Meeting, Philadelphia, PA May 7, 2001 for the work entitled: \"Bicaudate ratio as a marker of brain atrophy in multiple sclerosis\".

See publications for this provider. (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.

As of 2025-12-08, Dr. Bermel has reported the financial relationships with the companies listed below.

Consulting and/or Speaking. Dr. Bermel receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Novartis Pharmaceuticals Corporation
• Roche (Hoffman-La Roche, Ltd.)
• Sanofi Genzyme

Right to Future Distribution of Cleveland Clinic Financial Interest. Dr. Bermel may receive future financial benefits from the Cleveland Clinic for inventions or discoveries commercialized through the companies shown below:

• Qr8 Health, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.